

17th June 2025

## **Drug Availability**

## **Availability of Capecitabine 500mg Tablets**

Dear Valued Client,

HPS Pharmacies wish to advise that both suppliers are experiencing a supply interruption for capecitabine 500mg tablets as follows:

## Xelabine

Capecitabine 500mg ARTG 213045

## Capecitabine Sandoz Capecitabine 500mg ARTG 201800

This supply interruption is expected to be resolved by the end of July 2025.

An internationally registered alternative has been approved for supply under Section 19A of the *Therapeutic Goods Act 1989*. This product is registered in the US and all labelling is in English.

Please note that S19A products may have a longer lead time as they must be sourced internationally.

Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.

This notice only applies to the 500mg presentation. Capecitabine 150mg tablets are currently available.

Should you require further information regarding this matter, please contact your pharmacist at <u>HPS Pharmacies</u>.

Kind regards, Sallie Drake BPharm Clinical Communications Coordinator, HPS e <u>sallie.drake@hps.com.au</u> m 0408 341 662 <u>www.hps.com.au</u>

Copyright © 2025. All rights reserved.

Our mailing address is:

HPS Corporate Head Office

PO Box 7300

Melbourne VIC 3004